Abstract:The administration of pioglitazone as an oral therapy is restricted due to various challenges. The aim of the current investigation was to evaluate the suitability of pioglitazone in adhesive transdermal patch as an alternative delivery system, in order to improve therapeutic delivery. Drug in adhesive pioglitazone (2% w/w) transdermal patch were optimized for drug release, suitable adhesive, and skin permeation enhancer. The selected patch was examined for drug-loading capacity and the patch with greater piog… Show more
“…Regarding the effects observed during the use of pioglitazone, it has been mainly reported that it increases insulin sensitivity, interference with lipid homeostasis, and regulation of the inflammatory response. Thus, many efforts have been made in the development of formulations for the topical use of pioglitazone ( Silva-Abreu et al., 2017 ; Nair et al., 2019 ; Rojewska et al., 2020 ), opening new expectations for the treatment of skin diseases such as CL. Indeed, patients with psoriasis treated with topical pioglitazone had a decreased severity in disease score ( Mittal et al., 2009 ; Singh and Anil, 2016 ).…”
Patients with cutaneous leishmaniasis (CL) due to Leishmania braziliensis infection have an exacerbated inflammatory response associated with tissue damage and ulcer development. An increase in the rate of patients who fail therapy with pentavalent antimony has been documented. An adjuvant therapy with an anti-inflammatory drug with the potential of Leishmania killing would benefit CL patients. The aim of the present study was to investigate the contribution of peroxisome proliferator-activated receptor-γ (PPAR-γ) activation by pioglitazone in the regulation of the inflammatory response and L. braziliensis killing by monocytes. Pioglitazone is an oral drug used in the treatment of diabetes, and its main mechanism of action is through the activation of PPAR-γ, which is expressed in many cell types of the immune response. We found that activation of PPAR-γ by pioglitazone decreases the inflammatory response in CL patients without affecting L. braziliensis killing by monocytes. Our data suggest that pioglitazone may serve as an adjunctive treatment for CL caused by L. braziliensis.
“…Regarding the effects observed during the use of pioglitazone, it has been mainly reported that it increases insulin sensitivity, interference with lipid homeostasis, and regulation of the inflammatory response. Thus, many efforts have been made in the development of formulations for the topical use of pioglitazone ( Silva-Abreu et al., 2017 ; Nair et al., 2019 ; Rojewska et al., 2020 ), opening new expectations for the treatment of skin diseases such as CL. Indeed, patients with psoriasis treated with topical pioglitazone had a decreased severity in disease score ( Mittal et al., 2009 ; Singh and Anil, 2016 ).…”
Patients with cutaneous leishmaniasis (CL) due to Leishmania braziliensis infection have an exacerbated inflammatory response associated with tissue damage and ulcer development. An increase in the rate of patients who fail therapy with pentavalent antimony has been documented. An adjuvant therapy with an anti-inflammatory drug with the potential of Leishmania killing would benefit CL patients. The aim of the present study was to investigate the contribution of peroxisome proliferator-activated receptor-γ (PPAR-γ) activation by pioglitazone in the regulation of the inflammatory response and L. braziliensis killing by monocytes. Pioglitazone is an oral drug used in the treatment of diabetes, and its main mechanism of action is through the activation of PPAR-γ, which is expressed in many cell types of the immune response. We found that activation of PPAR-γ by pioglitazone decreases the inflammatory response in CL patients without affecting L. braziliensis killing by monocytes. Our data suggest that pioglitazone may serve as an adjunctive treatment for CL caused by L. braziliensis.
“…The micrograph of the film was captured on a Nova NanoSEM 450 (FEI Ltd., Hillsboro, OR, USA) equipped with a large field detector. The film was mounted using silver electrical tape and sputter coated (SCD005 Baltek Sputter Coater, Baltec, AG, Balzers, Liechtenstein, Germany) with gold in the presence of argon gas under reduced pressure [ 32 ].…”
The reduced therapeutic efficacy of rizatriptan in migraine treatment is primarily due to low oral bioavailability and extensive first pass metabolism. The purpose of this investigation was to optimize the thin mucoadhesive buccal film of rizatriptan and assess the practicability of its development as a potential substitute for conventional migraine treatment. Buccal films (FR1–FR10) were fabricated by a conventional solvent casting method utilizing a combination of polymers (Proloc, hydroxypropyl methylcellulose and Eudragit RS 100). Drug-loaded buccal films (F1–F4) were examined for mechanical, mucoadhesive, swelling and release characteristics. In vivo pharmacokinetics parameters of selected buccal film (F1) in rabbits were compared to oral administration. Films F1–F4 displayed optimal physicomechanical properties including mucoadhesive strength, which can prolong the buccal residence time. A biphasic, complete and higher drug release was seen in films F1 and F4, which followed Weibull model kinetics. The optimized film, F1, exhibited significantly higher (p < 0.005) rizatriptan buccal flux (71.94 ± 8.26 µg/cm2/h) with a short lag time. Film features suggested the drug particles were in an amorphous form, compatible with the polymers used and had an appropriate surface morphology suitable for buccal application. Pharmacokinetic data indicated a significantly higher rizatriptan plasma level (p < 0.005) and Cmax (p < 0.0001) upon buccal film application as compared to oral solution. The observed AUC0–12h (994.86 ± 95.79 ng.h/mL) in buccal treatment was two-fold higher (p < 0.0001) than the control, and the relative bioavailability judged was 245%. This investigation demonstrates the prospective of buccal films as a viable and alternative approach for effective rizatriptan delivery.
“…This patch gained the largest share of the nitroglycerin industry. Nitro-Dur II ® was the brand name for the patch, which was later sold and listed in a US patent [77].…”
Section: From the Ointment To The Transdermal Patches: Nitroglycerin ...mentioning
Topical delivery methods have been used since the dawn of time, employed to cure a wide range of ailments and for aesthetic purposes. Transdermal drug delivery has evolved throughout time, with the development of passive and active technologies that have resulted in enhanced distribution, accuracy in drug dosage, and better fulfilment of the requirements of the individual. The search for more powerful pharmaceuticals that can be delivered to the skin through appropriate transdermal technologies will continue to be a focus in the development of drugs for transdermal patches and other forms of delivery. Topical and transdermal distribution has been around for a while, but this review will focus on transdermal patches and how they've evolved. The articles have been searched on different search engines such as Scopus database, Science direct, PubMed, Google scholar, and Bentham science using multiple keywords. An adhesive transdermal patch is applied to the skin and contains medicine that is absorbed into the bloodstream through the skin. It aids in the recovery of an afflicted part of the body. When compared to oral, topical, i. v., and i. m. administration systems, transdermal drug delivery allows a controlled release of the medicine into patients, often by either a porous membrane or by body heat melting small layers of medication embedded in the adhesive. The fundamental drawback of transdermal delivery methods is that the skin is a highly efficient barrier, therefore, only tiny molecules can enter the skin and be administered in this manner.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.